DOI: https://doi.org/10.15587/2519-4798.2017.99566

Диагностическое значение уровня галектина-3 у больных гипертрофической кардиомиопатией

Daghar Samaouil

Анотація


Целью исследования было изучение уровня галектина-3 у больных с гипертрофической кардимиопатией в зависимости от особенностей клинического течения заболевания, наличия осложнений и сопутствующей патологии для определения возможности его использования в качестве биомаркера ГКМП. Результаты исследования свидетельствуют о значительной вариабельности данного биомаркера, на уровень которого оказывают влияние возраст больного, наличие осложнений и сопутствующей патологии


Ключові слова


галектин-3; диагностическое значение; гипертрофическая кардиомиопатия; клиническое течение; осложнения; сопутствующая патология

Повний текст:

PDF (Русский)

Посилання


Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P. et. al. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35 (39), 2733–2779. doi: 10.1093/eurheartj/ehu284

Chen, Y.-Z., Qiao, S.-B., Hu, F.-H., Yuan, J.-S., Yang, W.-X., Cui, J.-G. et. al. (2015). Left ventricular remodeling and fibrosis: Sex differences and relationship with diastolic function in hypertrophic cardiomyopathy. European Journal of Radiology, 84 (8), 1487–1492. doi: 10.1016/j.ejrad.2015.04.026

Hussain, T., Dragulescu, A., Benson, L., Yoo, S.-J., Meng, H., Windram, J. et. al. (2015). Quantification and Significance of Diffuse Myocardial Fibrosis and Diastolic Dysfunction in Childhood Hypertrophic Cardiomyopathy. Pediatric Cardiology, 36 (5), 970–978. doi: 10.1007/s00246-015-1107-7

Li, A.-H., Liu, P. P., Villarreal, F. J., Garcia, R. A. (2014). Dynamic Changes in Myocardial Matrix and Relevance to Disease: Translational Perspectives. Circulation Research, 114 (5), 916–927. doi: 10.1161/circresaha.114.302819

O’Hanlon, R., Grasso, A., Roughton, M., Moon, J. C., Clark, S., Wage, R. et. al. (2010). Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 56 (11), 867–874. doi: 10.1016/j.jacc.2010.05.010

Lakomkin, S. V., Skvortsov, A. A., Goryunova, T. V., Masenko, V. P., Tereshchenko, S. N. (2012). Galektin-3 – novyy marker diagnostiki i prognoza khronicheskoy serdechnoy nedostatochnosti. Kardiologiya, 3, 45–52.

Li, L.-c., Li, J., Gao, J. (2014). Functions of Galectin-3 and Its Role in Fibrotic Diseases. Journal of Pharmacology and Experimental Therapeutics, 351 (2), 336–343. doi: 10.1124/jpet.114.218370

Yu, X., Sun, Y., Zhao, Y., Zhang, W., Yang, Z., Gao, Y. et. al. (2015). Prognostic Value of Plasma Galectin-3 Levels in Patients With Coronary Heart Disease and Chronic Heart Failure. International Heart Journal, 56 (3), 314–318. doi: 10.1536/ihj.14-304

Wu, C.-K., Su, M.-Y., Lee, J.-K., Chiang, F.-T., Hwang, J.-J., Lin, J.-L. et. al. (2015). Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Scientific Reports, 5, 17007. doi: 10.1038/srep17007

Christenson, R. H., Duh, S.-H., Wu, A. H. B., Smith, A., Abel, G., deFilippi, C. R. et. al. (2010). Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clinical Biochemistry, 43 (7-8), 683–690. doi: 10.1016/j.clinbiochem.2010.02.001

De Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L. et. al. (2011). The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine, 272 (1), 55–64. doi: 10.1111/j.1365-2796.2011.02476.x

Lok, D. J. A., Van Der Meer, P., de la Porte, P. W. B.-A., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., van Veldhuisen, D. J. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clinical Research in Cardiology, 99 (5), 323–328. doi: 10.1007/s00392-010-0125-y

Grandin, E. W., Jarolim, P., Murphy, S. A., Ritterova, L., Cannon, C. P., Braunwald, E., Morrow, D. A. (2011). Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. Clinical Chemistry, 58 (1), 267–273. doi: 10.1373/clinchem.2011.174359

Tseluyko, V. Y., Matviychuk, N. V., Kinoshenko, K. Yu. (2014). Galektin-3 u khvorikh na khronichnu sertsevu nedostatnist. Ukrayins'kyy kardiolohichnyy zhurnal, 3, 77–81.

Tseluyko, V. I., Vashakidze, Z. S., Motylevskaya, T. V., Opolonskaya N. A. (2012). Galektin-3 u bol'nykh s fibrillyatsiyey predserdiy. Ukrayins'kyy kardiolohichnyy zhurnal, 3, 45–49.

Tseluyko, V. I., Zhadan, A. V., Zedginidze, E. (2015). Galektin-3 i obratnoye remodelirovaniye serdtsa posle khirurgicheskoy korrektsii nedostatochnosti mitral'nogo klapana. Ukrayins'kyy kardiolohichnyy zhurnal, 6, 79–82.


Пристатейна бібліографія ГОСТ


Elliott, P. M. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) [Text] / P. M. Elliott, A. Anastasakis, M. A. Borger, M. Borggrefe, F. Cecchi, P. Charron et. al. // European Heart Journal. – 2014. – Vol. 35, Issue 39. – P. 2733–2779. doi: 10.1093/eurheartj/ehu284 

Chen, Y.-Z. Left ventricular remodeling and fibrosis: Sex differences and relationship with diastolic function in hypertrophic cardiomyopathy [Text] / Y.-Z. Chen, S.-B. Qiao, F.-H. Hu, J.-S. Yuan, W.-X. Yang, J.-G. Cui et. al. // European Journal of Radiology. – 2015. – Vol. 84, Issue 8. – P. 1487–1492. doi: 10.1016/j.ejrad.2015.04.026 

Hussain, T. Quantification and significance of diffuse myocardial fibrosis and diastolic dysfunction in childhood hypertrophic cardiomyopathy [Text] / T. Hussain, A. Dragulescu, L. Benson, S.-J. Yoo, H. Meng, J. Windram et. al. // Pediatric Cardiology. – 2015. – Vol. 36, Issue 5. – P. 970–978. doi: 10.1007/s00246-015-1107-7 

Li, A.-H. Dynamic changes in myocardial matrix and relevance to disease [Text] / A.-H. Li, P. P. Liu, F. J. Villarreal, R. A. Garcia // Circulation Research. – 2014. – Vol. 114, Issue 5. – P. 916–927. doi: 10.1161/circresaha.114.302819 

O’Hanlon, R. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy [Text] / R. O’Hanlon, A. Grasso, M. Roughton, J. C. Moon, S. Clark, R. Wage et. al. // Journal of the American College of Cardiology. – 2010. – Vol. 56, Issue 11. – P. 867–874. doi: 10.1016/j.jacc.2010.05.010 

Лакомкин, С. В. Галектин-3 – новый маркер диагностики и прогноза хронической сердечной недостаточности [Текст] / С. В. Лакомкин, А. А. Скворцов, Т. В. Горюнова, В. П. Масенко, С. Н. Терещенко // Кардиология. – 2012. – № 3. – С. 45–52.

Li, L.-c. Functions of galectin-3 and its role in fibrotic diseases [Text] / L.-c. Li, J. Li, J. Gao // Journal of Pharmacology and Experimental Therapeutics. – 2014. – Vol. 351, Issue 2. – P. 336–343. doi: 10.1124/jpet.114.218370 

Yu, X. Prognostic Value of Plasma Galectin-3 Levels in Patients With Coronary Heart Disease and Chronic Heart Failure [Text] / X. Yu, Y. Sun, Y. Zhao, W. Zhang, Z. Yang, Y. Gao et. al. // International Heart Journal. – 2015. – Vol. 56, Issue 3. – P. 314–318. doi: 10.1536/ihj.14-304 

Wu, C.-K. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices [Text] / C.-K. Wu, M.-Y. Su, J.-K. Lee, F.-T. Chiang, J.-J. Hwang, J.-L. Lin et. al. // Scientific Reports. – 2015. – Vol. 5. – P. 17007. doi: 10.1038/srep17007 

Christenson, R. H. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure [Text] / R. H. Christenson, S.-H. Duh, A. H. B. Wu, A. Smith, G. Abel, C. R. deFilippi et. al. // Clinical Biochemistry. – 2010. – Vol. 43, Issue 7-8. – P. 683–690. doi: 10.1016/j.clinbiochem.2010.02.001 

De Boer, R. A. The fibrosis marker galectin-3 and outcome in the general population [Text] / R. A. De Boer, D. J. van Veldhuisen, R. T. Gansevoort, A. C. Muller Kobold, W. H. van Gilst, H. L. Hillege et. al. // Journal of Internal Medicine. – 2011. – Vol. 272, Issue 1. – P. 55–64. doi: 10.1111/j.1365-2796.2011.02476.x 

Lok, D. J. A. Prognostic value of galectin-3, anovel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study [Text] / D. J. A. Lok, P. Van Der Meer, P. W. B.-A. de la Porte, E. Lipsic, J. Van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen // Clinical Research in Cardiology. – 2010. – Vol. 99, Issue 5. – P. 323–328. doi: 10.1007/s00392-010-0125-y 

Grandin, E. W. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 [Text] / E. W. Grandin, P. Jarolim, S. A. Murphy, L. Ritterova, C. P. Cannon, E. Braunwald, D. A. Morrow // Clinical Chemistry. – 2011. – Vol. 58, Issue 1. – P. 267–273. doi: 10.1373/clinchem.2011.174359 

Целуйко, В. И. Галектин-3 у хворих на хронічну серцеву недостатність [Текст] / В. Й. Целуйко, Н. В. Матвійчук, К. Ю. Кіношенко // Український кардіологічний журнал. – 2014. – № 3. – С. 77–81.

Целуйко, В. И. Галектин-3 у больных с фибрилляцией предсердий [Текст] / В. И. Целуйко, З. С. Вашакидзе, Т. В. Мотылевская, Н. А. Ополонская // Український кардіологічний журнал. – 2012. – № 3. – С. 45–49.

Целуйко, В. И. Галектин-3 и обратное ремоделирование сердца после хирургической коррекции недостаточности митрального клапана [Текст] / В. И. Целуйко, А. В. Жадан, Э. Зедгинидзе // Український кардіологічний журнал. – 2015. – № 6. – С. 79–82.







Copyright (c) 2017 Daghar Samaouil

Creative Commons License
Ця робота ліцензована Creative Commons Attribution 4.0 International License.

ISSN 2519-4798 (Online), ISSN 2519-478X (Print)